Our data show an improvement in these immune and liver disease biomarkers in plasma (immune exhaustion (PD1), chemokines (CXCL10, CCL2, and CXCL8), and cytokines (IL10)) after achieving SVR with DAA therapy in HIV/HCV-coinfected individuals. The gene discussed is CXCL10; the disease is liver disorder.